DDX27 (DEAD-box helicase 27) is an ATP-dependent RNA helicase that functions as a component of the nucleolar ribosomal RNA (rRNA) processing machinery, regulating 3' end formation of 47S rRNA 1. Beyond its canonical role in ribosome biogenesis, DDX27 plays a pivotal role in RNA metabolism, including transcription, pre-mRNA splicing, and translation 2. Mechanistically, DDX27 promotes cancer progression through multiple pathways. It enhances ERK1/2 phosphorylation and NF-κB signaling activation, with the latter occurring through interaction with nucleophosmin 1 (NPM1) 34. DDX27 also promotes epithelial-mesenchymal transition (EMT) and enhances stem cell-like properties in cancer cells 56. Clinically, elevated DDX27 expression correlates with poor prognosis across multiple malignancies including colorectal cancer, gastric cancer, breast cancer, hepatocellular carcinoma, and oral squamous cell carcinoma 25. High DDX27 expression associates with advanced disease stages, metastasis, chemoresistance, and reduced overall and disease-free survival 46. Therapeutic strategies targeting DDX27 include RNA interference (siRNA/shRNA), miRNA-based therapies, NF-κB pathway inhibitors, and combination approaches with chemotherapy 25, positioning DDX27 as a promising biomarker and therapeutic target.